- cafead Jul 09, 2024 at 12:12: PM
via As Gilead Sciences tussles with a web of HIV drug litigation, a high-stakes case tied to patents for prevention medicines is coming back to test the drugmaker.
On Friday, the U.S. Department of Justice appealed Gilead’s May 2023 victory in a Delaware court, which found that use of Gilead's pre-exposure prophylaxis (PrEP) regimens did not infringe three key patents the U.S. has credited to the CDC.
article source
On Friday, the U.S. Department of Justice appealed Gilead’s May 2023 victory in a Delaware court, which found that use of Gilead's pre-exposure prophylaxis (PrEP) regimens did not infringe three key patents the U.S. has credited to the CDC.
article source